Stock Watch - ChinaBio® Today

Recent Articles

Simcere Given OK by SFDA for Flu Drug Relenza Feb 11, 2010: Simcere Pharma (先声药业) reported it has received SFDA approval to manufacture and market Relenza (zanamivir), the flu treatment developed by GlaxoSmithKline (NYSE: GSK). Relenza, an inhaled neuraminidase inhibitor, is one of only two approved drugs for treating H1N1 flu. Simcere holds an exclusive license for Relenza in China. More details...

Stock Symbol: (NYSE: SCR)

Sinovac Prices Secondary Offering Jan 28, 2010: Sinovac Biotech (北京科兴生物制品有限公司) upped its secondary stock issue to 10 million shares (from 8.65 million) and priced them at $5.75 each, a 6% discount from last night’s closing price of $6.11. The company said it expects net proceeds of $53.8 million ($62 million if the underwriters purchase an additional 1.3 million shares for overallotments). Sinovac’s business focus is on the currently hot vaccine sector. More details...

Stock Symbol: (NSDQ: SVA)

Sinovac Issues 2009 Guidance; Announces Secondary Stock Issue Jan 21, 2010: Sinovac Biotech (北京科兴生物制品有限公司) released full-year guidance for 2009 and also announced it would issue 8.65 million shares to raise about $62 million in new capital. The company said it expects revenues for 2009 to be between $81 and $85 million, while gross profits will total somewhere in a $61 to $65 million range. More details...

Stock Symbol: (NSDQ: SVA)

Mindray Medical Will Beat Analysts’ 2009 Predictions Jan 11, 2010: Mindray Medical (迈瑞医疗国际有限公司), the Shenzhen medical device company, said it expects 2009 revenues will total between $624 million and $633 million, representing a 15% improvement over year-earlier results. Earnings per share (non-GAAP) will be not less than $1.29. Those results were well ahead of analysts’ estimates, which called for $621 million in revenue and eps of $1.21. More details...

Stock Symbol: (NYSE: MR)

Mindray Medical Reviews New Products and Reveals Future Plans Jan 7, 2010: Mindray Medical, the Shenzhen-located maker of medical devices, reported it exceeded its new product introduction goal for 2009 by releasing ten products, bringing its total product count to 70. It expects to launch an additional seven to ten new products in 2010. More details...

Stock Symbol: (NYSE: MR)

China-listed Life Science IPOs Are Hot Dec 31, 2009: In mid-summer, China lifted its IPO ban, allowing companies once again to access public markets. The first entry, a successful transaction, was Guilin Sanjin Pharmaceutical Co., which ended the year with a 41% increase. But the life science companies that listed on the ChiNext did even better -- often providing a 100% return or better. All of this is in sharp contrast to the experience of life science companies that chose to list on US exchanges. More details...

Stock Symbol: (SZ: 002275)

Mixed Results for China Life Science US IPOs Dec 30, 2009: In the last two months, three China life science companies have made their debuts on US exchanges. The most important insight from these IPOs is that they actually took place. In the previous 12 months, the worldwide economic crisis prevented almost all IPO activity, so a completed IPO became reason enough to celebrate. With that being said, the three companies – China Nuokang Bio-Pharma, Concord Medical and China Cord Blood – did not fare particularly well in their debuts. More details...

Stock Symbols: (NSDQ: NKBP) (NYSE: CCM) (NYSE: CO)

Disappointing Pricing for China Nuokang’s Nasdaq IPO Dec 10, 2009: China Nuokang Bio-Pharmaceutical priced its IPO at $9, which was slightly below the expected range of $10-$12. When the shares began trading today, they fell further, dropping 56 cents to $8.44, a loss of about 6%. The company receives 94% of its revenues from a single product, the hemocoagulant Baqueting, which is derived from the venom of the pit viper. More details...

Stock Symbol: (NSDQ: NKBP)

Tianyin Pharma Calls for 75% Improvement in 2011 Results Dec 3, 2009: Tianyin Pharmaceutical, Co., a modernized TCM company, issued guidance calling for a 75% improvement in fiscal year 2011 (ending June 30, 2011) results. The company said it expects revenue of $113 million for fiscal 2011, up from $63.6 million in 2010, and net income of $19.6 million, a rise from $11.3 million in the current year. More details..
Stock Symbol: (NYSE Alternext: TPI)

Sinovac Receives a 1 Million Dose Order for H1N1 Vaccine Dec 1, 2009: Sinovac Biotech Ltd. (北京科兴生物制品有限公司) announced the fourth purchase order for its H1N1 vaccine, PANFLU.1™, this one for 1 million doses. The latest order brings Sinovac’s total to 12.5 million doses, of which 7.6 million doses have already been delivered. Sinovac expects to complete the order early next year. More details...
Stock Symbol: (NYSE: SVA)